Sharp Daily
No Result
View All Result
Wednesday, August 6, 2025
  • Home
  • News
    • Politics
  • Business
    • Banking
  • Investments
  • Technology
  • Startups
  • Real Estate
  • Features
  • Appointments
  • About Us
    • Meet The Team
Sharp Daily
  • Home
  • News
    • Politics
  • Business
    • Banking
  • Investments
  • Technology
  • Startups
  • Real Estate
  • Features
  • Appointments
  • About Us
    • Meet The Team
No Result
View All Result
Sharp Daily
No Result
View All Result
Home Investments

Moderna To Establish mRNA Manufacturing Facility In Kenya

Editor SharpDaily by Editor SharpDaily
March 7, 2022
in Investments, News
Reading Time: 3 mins read
moderna

[Photo/ AP]

Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that with the assistance of the US Government, it has entered into a Memorandum of Understanding with the Government of the Republic of Kenya to establish Kenya as the location for the Company’s mRNA manufacturing facility.

Moderna is building this state-of-the-art mRNA facility in Africa with the goal of producing up to 500 million doses of vaccines each year. The Company anticipates investing up to $500 million in this new facility which will focus on drug substance manufacturing on the continent of Africa for the continent of Africa and could also be expanded to include fill/finish and packaging capabilities at the site. In parallel, Moderna is also working on plans to allow it to fill doses of its COVID-19 vaccine in Africa as early as 2023, subject to demand.

“Battling the COVID-19 pandemic over the last two years has provided a reminder of the work that must be done to ensure global health equity. Moderna is committed to being a part of the solution and today, we announce another step in this journey – an investment in the Republic of Kenya to build a drug substance mRNA manufacturing facility capable of supplying up to 500 million doses for the African continent each year,” said Stéphane Bancel, Chief Executive Officer of Moderna. “With our mRNA global public health vaccine program, including our vaccine programs against HIV and Nipah, and with this partnership with the Republic of Kenya, the African Union and the U.S. Government, we believe that this step will become one of many on a journey to ensure sustainable access to transformative mRNA innovation on the African continent and positively impact public health”, he added.

Read: Caroline Armstrong-Ogwapit Appointed New Faces New Voices Trust Chairperson

RELATEDPOSTS

No Content Available

“We would like to thank the Government of the Republic of Kenya for their support in bringing our mRNA manufacturing facility to Kenya. We would also like to thank the U.S. Government for assisting us in this process,” said Noubar Afeyan, Co-founder and Chairman of Moderna. “We are honored to have played such a critical role in combatting the COVID-19 pandemic with our vaccine and we are determined to expand our global impact with our first manufacturing facility on the continent of Africa”, he continued.

“We are pleased to partner with Moderna in the establishment of this mRNA manufacturing facility to help prepare the country and our sister states on the continent through the African Union to respond to future health crises and stave off the next pandemic,” said His Excellency Uhuru Kenyatta, President of the Republic of Kenya. “This partnership is a testament to the capabilities of our community and our commitment to technological innovation. Moderna’s investment in Kenya will help advance equitable global vaccine access and is emblematic of the structural developments that will enable Africa to become an engine of sustainable global growth”, the President added. “Kenya recognizes and appreciates the collaboration of Moderna in building our local manufacturing capacity. This will ensure as a country and region we can quickly respond to health demands requiring Vaccine commodities”, said Sen. Mutahi Kagwe, Cabinet Secretary for Health of the Republic of Kenya.

In its prophylactic vaccines modality, Moderna’s mRNA pipeline includes 28 vaccine programs including vaccines against respiratory viruses, vaccines against latent viruses and vaccines against threats to global public health.

Read: Kenya’s Wealthy Plan ‘Second Nationalities’ To Access More Investments, Better Education, And Quality Healthcare

Previous Post

Caroline Armstrong-Ogwapit Appointed New Faces New Voices Trust Chairperson

Next Post

Daniel Muriungi Mugao Appointed Invesco Assurance CEO

Editor SharpDaily

Editor SharpDaily

The latest in business, real estate, education, investments, tech and entrepreneurship, brought to you daily. Reach us through thesharpdaily@gmail.com

Related Posts

1049795356
Analysis

Maximizing Your Pension Contributions

August 1, 2025
Analysis

Kenya’s Interest Rate Cut: A Turning Point for Growth

July 31, 2025
commercial illustrator
News

Why Kenyan private equity firms should consider continuation funds as an exit strategy

July 23, 2025
Analysis

Transferring Your Retirement Benefits Between Pension Schemes in Kenya

July 23, 2025
Investments

Invest in stability: introducing the Cytonn USD money market fund

July 18, 2025
Analysis

Park your money where it grows: Why more Kenyans are turning to Cytonn Money Market Fund

July 16, 2025

LATEST STORIES

EABL posts 12.2% profit surge, strengthens regional footprint despite rising illicit trade

August 1, 2025
1049795356

Maximizing Your Pension Contributions

August 1, 2025

The functional role of narrative in financial markets

August 1, 2025

Tanzania’s protectionist shift and what it means for Kenyan entrepreneurs and regional trade

July 31, 2025

Kenya’s Interest Rate Cut: A Turning Point for Growth

July 31, 2025

Why Syokimau, a satellite town is attracting real estate investors

July 31, 2025

Shri Krishana Overseas lists on NSE

July 25, 2025

Why young professionals should care about pensions

July 23, 2025
  • About Us
  • Meet The Team
  • Careers
  • Privacy Policy
  • Terms and Conditions
Email us: editor@thesharpdaily.com

Sharp Daily © 2024

No Result
View All Result
  • Home
  • News
    • Politics
  • Business
    • Banking
  • Investments
  • Technology
  • Startups
  • Real Estate
  • Features
  • Appointments
  • About Us
    • Meet The Team

Sharp Daily © 2024